+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Canine Atopic Dermatitis Market- Growth, Trends, and Forecast(2020 - 2025)

  • ID: 5176321
  • Report
  • August 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Ceva
  • Elanco
  • Kindred Biosciences Inc.
  • Toray Industries Inc.
  • Virbac
  • MORE
The canine atopic dermatitis market is expected to register a CAGR of 8.9% over the forecast period due to rising pollution, related to allergens, and increasing R&D activities.
  • Environmental factors are responsible for many of the allergies and diseases. According to the Journal of Toxicology, in 2017, it was observed that there is a direct proportion between the worsening of allergic conditions, such as atopic dermatitis, and the rising of environmental pollution.
  • Furthermore, increasing R&D activities are also expected to drive the market. For instance, recently, Boragen partnered with one of the global leading animal health companies, exclusively for the R&D activity related to the development of new treatment of canine atopic dermatitis. Hence, such factors are expected to boost the canine atopic dermatitis market.
Key Market Trends

The Monoclonal Antibodies Segment is Expected to Exhibit a Significant Market Growth

The monoclonal antibodies segment is expected to exhibit a thriving market growth over the forecast period. The major attributable factors are rising environmental pollution and the development of products.
  • According to the Journal of Toxicologic Pathology, 2017, environmental chemicals, like phthalate ester, that are involved in plastic manufacturing are observed to worsen atopic dermatitis. Also, nanomaterials and sand dust are responsible for elevating the allergic inflammation.
  • Furthermore, in 2019, Kindred Biosciences developed a monoclonal antibody for the treatment of canine atopic dermatitis, “Interleukin-31”. It completed its pilot study and showed a significant outcome. Hence, the advancements in products are expected to positively influence the market.
North America is Expected to Hold a Significant Share in the Market during the Forecast Period

North America is expected to be a dominant region for the canine atopic dermatitis market, owing to increasing spending in R&D activities. According to the Animal Health Institute, the animal health industry in the United States serves around 640 million food animals and 383 million companion animals.
  • In 2016, the pharmaceutical companies produced medicines worth around USD 11.6 billion. Furthermore, according to the American Veterinary Medical Association, in 2018, around 113,394 veterinary doctors were present in the United States. Hence, the presence of such skilled professionals is expected to positively influence the market.
Competitive Landscape

Some of the key players that are expected to be dominant in the canine atopic dermatitis market are Zoetis, Elanco, Virbac, Toray Industries Inc., Boehringer Ingelheim, Kindred Biosciences Inc., and Ceva.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Ceva
  • Elanco
  • Kindred Biosciences Inc.
  • Toray Industries Inc.
  • Virbac
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Pollution Related to Allergens
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 Usage of Off-label Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Glucocorticoids
5.1.2 Immuno-suppressants
5.1.3 Monoclonal Antibody
5.1.4 Other Treatment Types
5.2 By Route of Administration
5.2.1 Topical
5.2.2 Oral
5.2.3 Injectable
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Zoetis
6.1.2 Elanco
6.1.3 Virbac
6.1.4 Toray Industries Inc.
6.1.5 Boehringer Ingelheim
6.1.6 Kindred Biosciences Inc.
6.1.7 Ceva

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Zoetis
  • Elanco
  • Virbac
  • Toray Industries Inc.
  • Boehringer Ingelheim
  • Kindred Biosciences Inc.
  • Ceva
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll